ATE277596T1 - Topische pharmazeutische zusammensetzung, enthaltend einen cholinergischen wirkstoff oder einen kalziumkanalblocker - Google Patents

Topische pharmazeutische zusammensetzung, enthaltend einen cholinergischen wirkstoff oder einen kalziumkanalblocker

Info

Publication number
ATE277596T1
ATE277596T1 AT98907038T AT98907038T ATE277596T1 AT E277596 T1 ATE277596 T1 AT E277596T1 AT 98907038 T AT98907038 T AT 98907038T AT 98907038 T AT98907038 T AT 98907038T AT E277596 T1 ATE277596 T1 AT E277596T1
Authority
AT
Austria
Prior art keywords
cholinergic
act
pharmaceutical composition
composition containing
calcium channel
Prior art date
Application number
AT98907038T
Other languages
English (en)
Inventor
Michael Albert Kamm
Robin Kenneth Stewart Phillips
Original Assignee
Sla Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32475044&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE277596(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9703750.1A external-priority patent/GB9703750D0/en
Priority claimed from GBGB9727238.9A external-priority patent/GB9727238D0/en
Application filed by Sla Pharma Ag filed Critical Sla Pharma Ag
Application granted granted Critical
Publication of ATE277596T1 publication Critical patent/ATE277596T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Steroid Compounds (AREA)
AT98907038T 1997-02-24 1998-02-23 Topische pharmazeutische zusammensetzung, enthaltend einen cholinergischen wirkstoff oder einen kalziumkanalblocker ATE277596T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9703750.1A GB9703750D0 (en) 1997-02-24 1997-02-24 Treatment of haemorrhoids
GBGB9727238.9A GB9727238D0 (en) 1997-12-23 1997-12-23 Pharmaceutical composition
PCT/GB1998/000575 WO1998036733A2 (en) 1997-02-24 1998-02-23 Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker
US10/214,333 US20040028752A1 (en) 1997-02-24 2002-08-08 Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker

Publications (1)

Publication Number Publication Date
ATE277596T1 true ATE277596T1 (de) 2004-10-15

Family

ID=32475044

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98907038T ATE277596T1 (de) 1997-02-24 1998-02-23 Topische pharmazeutische zusammensetzung, enthaltend einen cholinergischen wirkstoff oder einen kalziumkanalblocker

Country Status (13)

Country Link
US (3) US20040028752A1 (de)
EP (3) EP1249238A3 (de)
JP (3) JP3352095B2 (de)
CN (3) CN1127333C (de)
AT (1) ATE277596T1 (de)
AU (1) AU733047C (de)
CA (1) CA2281755C (de)
DE (1) DE69826644T2 (de)
DK (1) DK0969813T3 (de)
ES (1) ES2224362T3 (de)
IL (2) IL131477A0 (de)
PT (1) PT969813E (de)
WO (1) WO1998036733A2 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT719145E (pt) 1994-05-27 2001-01-31 Cellegy Pharma Inc Composicao dadora de oxido nitrico para tratamento de desordens anais
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US20060140984A1 (en) 2002-10-25 2006-06-29 Foamix Ltd. Cosmetic and pharmaceutical foam
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US20080317679A1 (en) * 2002-10-25 2008-12-25 Foamix Ltd. Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US20060018937A1 (en) * 2002-10-25 2006-01-26 Foamix Ltd. Steroid kit and foamable composition and uses thereof
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US8119109B2 (en) * 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US20060233721A1 (en) * 2002-10-25 2006-10-19 Foamix Ltd. Foam containing unique oil globules
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US20080152596A1 (en) * 2005-07-19 2008-06-26 Foamix Ltd. Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof
CN100364540C (zh) * 2006-03-14 2008-01-30 北京大学 (2s-顺)-(+)-2,3-二氢-3-羟基-2-(4-甲氧苯基)-1,5-苯并硫氮杂䓬-4(5h)-酮在制备治疗肝炎的药物中的用途
DE102006038292A1 (de) * 2006-08-16 2008-02-21 Bayer Healthcare Ag Transdermale Anwendung von Triazinen zur Bekämpfung von Coccidien-Infektionen
EP2061463A4 (de) * 2006-09-01 2010-01-20 Moberg Derma Ab Topische zusammensetzung mit einem dihydropyridincalcium-antagonisten
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
AU2007356328A1 (en) * 2006-11-14 2009-01-15 Tal Berman Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses
ES2394375T3 (es) 2006-11-24 2013-01-31 Novartis Ag Composición para repeler y ahuyentar plagas
US20080292560A1 (en) * 2007-01-12 2008-11-27 Dov Tamarkin Silicone in glycol pharmaceutical and cosmetic compositions with accommodating agent
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
WO2009069006A2 (en) 2007-11-30 2009-06-04 Foamix Ltd. Foam containing benzoyl peroxide
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
WO2010041141A2 (en) 2008-10-07 2010-04-15 Foamix Ltd. Oil-based foamable carriers and formulations
AU2009205314A1 (en) 2008-01-14 2009-07-23 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US20120087872A1 (en) 2009-04-28 2012-04-12 Foamix Ltd. Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof
WO2011013009A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
CA2769677A1 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
AU2010302350B2 (en) 2009-10-02 2015-06-18 Journey Medical Corporation Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
ES2443847T3 (es) 2009-11-12 2014-02-20 Acacia Pharma Limited Uso de betanecol para el tratamiento de xerostomía
US12661407B2 (en) 2010-04-08 2026-06-23 Journey Medical Corporation Compositions, gels and foams with rheology modulators and uses thereof
GB201107533D0 (en) * 2011-05-06 2011-06-22 Acacia Pharma Ltd Formulaiton
ES2872081T3 (es) 2011-08-05 2021-11-02 Regeneron Pharma Ratones con cadena ligera universal humanizada
BR112014028610A2 (pt) * 2012-05-17 2017-06-27 Contract Pharmaceuticals Ltd formulações de vesícula não iônica de bloqueadores de canal de cálcio
US20140235570A1 (en) * 2013-02-19 2014-08-21 David Jonathan Hochman Therapeutic composition for the treatment of perianal disorders
RU2592366C2 (ru) * 2013-07-22 2016-07-20 Общество с ограниченной ответственностью "ХИЛИНГ ФАРМ" Фармакологическая композиция для лечения проктологических заболеваний (варианты)
WO2015051336A1 (en) 2013-10-03 2015-04-09 David Wise Compositions and methods for treating pelvic pain and other conditions
MX2020012139A (es) 2016-09-08 2021-01-29 Vyne Pharmaceuticals Inc Composiciones y metodos para tratar rosacea y acne.
TR201710576A2 (tr) * 2017-07-19 2019-02-21 Dokuz Eyluel Ueniversitesi Rektoerluegue Mi̇kroparti̇küler si̇stem i̇çeren anal fi̇ssür tedavi̇si̇ i̇çi̇n bi̇r tampon
BR102018008324A2 (pt) 2018-04-25 2019-11-05 Laboratórios Ferring Ltda. composição farmacêutica de uso tópico e processo de fabricação de composição farmacêutica de uso tópico
EP3801460B1 (de) * 2018-06-01 2025-03-12 Tavanta Therapeutics Hungary Incorporated Topische amlodipinsalze zur behandlung anorektaler krankheiten
RU2710742C1 (ru) * 2019-05-14 2020-01-10 Александра Александровна Савосина Композиция для лечения анальных трещин на основе фелодипина
RU2733080C1 (ru) * 2019-12-13 2020-09-29 Александр Евгеньевич Баранников Фармакологическая композиция для лечения проктологических заболеваний (варианты).
CN115337258B (zh) 2022-07-22 2024-10-15 上海奥全生物医药科技有限公司 一种盐酸地尔硫卓的药物组合物、制备方法及其应用
WO2026073242A1 (en) * 2024-09-30 2026-04-02 Auson Pharmaceuticals, Inc. Pharmaceutical composition of diltiazem hydrochloride, preparation method therefor, and application thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2074627A1 (en) * 1970-01-13 1971-10-08 Socres Ppsoriasis treatment compsn
JPS6016917A (ja) * 1983-07-08 1985-01-28 Yamanouchi Pharmaceut Co Ltd 塩酸ニカルジピンまたはニフエジピンの軟膏剤
JPS60109519A (ja) * 1983-11-17 1985-06-15 Nippon Shinyaku Co Ltd ニフェジピン坐剤
US4931279A (en) 1985-08-16 1990-06-05 Bausch & Lomb Incorporated Sustained release formulation containing an ion-exchange resin
JPS63170316A (ja) 1986-12-30 1988-07-14 Fujimoto Seiyaku Kk ニフエジピン経皮吸収外用製剤
JPS63174924A (ja) * 1987-01-14 1988-07-19 Toko Yakuhin Kogyo Kk 軟膏基剤および軟膏剤
IT1222395B (it) * 1987-07-30 1990-09-05 Pierrel Spa Composizione farmaceutica per somministrazione intranasale comprendente l'ormone ghrh,un agonista colinergico e/o un sale biliare
US5084281A (en) * 1989-02-14 1992-01-28 Dillon Richard S Method and solution for treating tissue wounds
BE1003002A6 (fr) 1989-03-21 1991-10-22 Coppe Jan Composition a mettre en oeuvre pour le traitement de la calvitie, et procedes faisant usage de celle-ci.
US5162315A (en) * 1989-05-08 1992-11-10 Rajadhyaksha Vithal J Penetration enhancers
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5534520A (en) 1990-04-10 1996-07-09 Fisher; Abraham Spiro compounds containing five-membered rings
ES2071332T3 (es) * 1990-08-13 1995-06-16 David W Yesair Particulas coloidales de lipidos mixtos-bicarbonato para administrar farmacos o calorias.
US5332576A (en) * 1991-02-27 1994-07-26 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5288505A (en) * 1991-06-26 1994-02-22 Galephar P.R., Inc., Ltd. Extended release form of diltiazem
SE9102340D0 (sv) * 1991-08-13 1991-08-13 Astra Ab Pharmaceutical composition containing carbachol and othercholinergic substances
WO1995006466A1 (en) * 1993-09-01 1995-03-09 Koren Laboratories Pty. Limited Treatment of anorectal disorders
JPH07145061A (ja) 1993-11-25 1995-06-06 Sekisui Chem Co Ltd 経皮吸収製剤
US5504117A (en) 1994-05-27 1996-04-02 Neptune Pharmaceutical Corporation Pharmacologic preparation for the treatment of anal disorders
PT719145E (pt) 1994-05-27 2001-01-31 Cellegy Pharma Inc Composicao dadora de oxido nitrico para tratamento de desordens anais
US5654337A (en) * 1995-03-24 1997-08-05 II William Scott Snyder Topical formulation for local delivery of a pharmaceutically active agent
IT1297886B1 (it) 1997-02-28 1999-12-20 Carmine Antropoli Nifedipina per uso topico

Also Published As

Publication number Publication date
EP0969813A2 (de) 2000-01-12
WO1998036733A3 (en) 1998-11-26
US20130079332A1 (en) 2013-03-28
IL131477A0 (en) 2001-01-28
AU733047C (en) 2002-05-16
EP1250927A3 (de) 2003-03-26
US8318721B2 (en) 2012-11-27
US20040028752A1 (en) 2004-02-12
WO1998036733A2 (en) 1998-08-27
PT969813E (pt) 2004-12-31
US8906903B2 (en) 2014-12-09
DE69826644D1 (de) 2004-11-04
DE69826644T2 (de) 2005-11-17
CA2281755C (en) 2006-11-07
US20110263568A1 (en) 2011-10-27
EP1249238A3 (de) 2003-03-26
CN1127333C (zh) 2003-11-12
CN1515261A (zh) 2004-07-28
EP0969813B1 (de) 2004-09-29
EP1249238A2 (de) 2002-10-16
CN1480139A (zh) 2004-03-10
EP1249238A8 (de) 2002-12-04
JP2002356422A (ja) 2002-12-13
IL178133A0 (en) 2006-12-31
CN100379423C (zh) 2008-04-09
EP1250927A2 (de) 2002-10-23
CN1248162A (zh) 2000-03-22
ES2224362T3 (es) 2005-03-01
JP3352095B2 (ja) 2002-12-03
DK0969813T3 (da) 2005-01-31
AU6302498A (en) 1998-09-09
JP2001517210A (ja) 2001-10-02
CA2281755A1 (en) 1998-08-27
JP2002356425A (ja) 2002-12-13
AU733047B2 (en) 2001-05-03

Similar Documents

Publication Publication Date Title
DE69826644D1 (de) Topische pharmazeutische zusammensetzung, enthaltend einen cholinergischen wirkstoff oder einen kalziumkanalblocker
BR0013704A (pt) Uso de inibidores do sistema renina-angiotensina na prevenção de casos cardiovasculares
IL195723A (en) Use of p53 inhibitors for the preparation of medicament
IL154888A (en) Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid
UA81638C2 (ru) Композиция метронидазола для местного применения для лечения заболеваний аноректального и перианального участков
ATE321529T1 (de) Dosierungsform für eine verzögerte und zunehmende wirkstoffsfreisetzung
AP2003002922A0 (en) Skin-permeable selective cyclooxygenase-2 inhibitor composition.
ES2166783T3 (es) Factor viii activado utilizado como agente terapeutico y metodo para el tratamiento de la deficiencia de factor viii.
MXPA04000654A (es) Terapia dermica usando derivados de fosfato de agente de transferencia de electrones.
KR970706794A (ko) 치핵 치료용 조성물 및 이의 사용방법(Hemorrhoidal compositions and method of use)
WO2005007072A3 (en) Methods and pharmaceutical compositions for healing wounds
WO2004039325A3 (en) Treatment of pain with jnk inhibitors
AR015744A1 (es) Uso de dexmedetomidina para sedacion en terapia intensiva
HUP9901360A2 (hu) Cimicifuga racemosa-ból származó extraktum alkalmazása
DK1280558T3 (da) Halvfast indgivelsesvehikel og farmaceutiske sammensætninger
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
NO20042758L (no) Fremgangsmate for behandling av en pasient som krever analgesi.
TW200420290A (en) Methods for the treatment, prevention and management of macular degeneration
PT1150704E (pt) Melagatran para o tratamento da inflamacao
IL148777A (en) Mirtazepine oral oral administration unit
SE9902597D0 (sv) New use
DK0927031T3 (da) Farmaceutisk sammensætning indeholdende nimesulid til oral admnistration
SE9700617D0 (sv) New composition
RU2000110676A (ru) Способ консервативного лечения стриктур уретры
EA199700025A1 (ru) Применение олигосахарида и аспирина для приготовления медикаментов, предназначенных для лечения тромбоэмболических заболеваний, фармацевтическая композиция, способ лечения

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0969813

Country of ref document: EP